Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

• Verfasst von: Neben, Kai [VerfasserIn]
• Verfasst von: Jauch, Anna [VerfasserIn]
• Verfasst von: Bertsch, Uta [VerfasserIn]
• Verfasst von: Raab, Marc-Steffen [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Hose, Dirk [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Titel: Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
• Verf.angabe: Kai Neben, Henk M. Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Hans Salwender, Igor W. Blau, Katja Weisel, Michael Pfreundschuh, Christof Scheid, Ulrich Dührsen, Walter Lindemann, Ingo G. H. Schmidt-Wolf, Norma Peter, Christian Teschendorf, Hans Martin, Mathias Haenel, Hans G. Derigs, Marc S. Raab, Anthony D. Ho, Helgi van de Velde, Dirk Hose, Pieter Sonneveld, and Hartmut Goldschmidt
• E-Jahr: 2012
• Jahr: January 26, 2012
• Umfang: 9 S.
• Fussnoten: Gesehen am 18.04.2018
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2012
• Band/Heft Quelle: 119(2012), 4, Seite 940-948
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood-2011-09-379164
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1572126205

Abstract

In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. In the present study, we analyzed the prognostic value of 12 chromosomal abnormalities in a series of 354 MM patients treated within the HOVON-65/GMMG-HD4 trial. Because of the 2-arm design of the study, we were able to analyze the effect of a bortezomib-based treatment before and after autologous stem cell transplantation (arm B) compared with standard treatment without bortezomib (arm A).